BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

Journal:

Journal of Clinical Oncology

Published:

2025-06-28

DOI:

10.1200/jco-24-02595

Affiliations:

24

Authors:

29

Go to article

Institutions	Authors	Share
Gregorio Marañon University Hospital, Spain	3.000000	0.10
Highlight Therapeutics Sl., Spain	3.000000	0.10
Pangaea Oncology SA, Spain	3.000000	0.10
CHU de Bordeaux, France	2.000000	0.07
Clínica Universidad de Navarra (CUN), UNAV, Spain	1.666667	0.06
CHU Nice, France	1.000000	0.03
HM Hospitales, Spain	1.000000	0.03
Merck - Rahway, United States of America (USA)	1.000000	0.03
Biomedical Research Institute of Murcia (IMIB), Spain	1.000000	0.03
Institute Gustave-Roussy (IGR), France	1.000000	0.03
Hospital Universitario Virgen Macarena, Spain	1.000000	0.03
Ambroise Paré Hospital, France	1.000000	0.03
University of Versailles Saint-Quentin-en-Yvelines (UVSQ), France	1.000000	0.03
Institute of Biomedicine of Seville (IBiS), Spain	1.000000	0.03
Alps Grenoble University Hospital (CHU Grenoble Alpes), France	1.000000	0.03
Consorci Hospital General Universitario de Valencia (CHGUV), Spain	1.000000	0.03
MD Anderson Cancer Center Madrid, Spain	1.000000	0.03
August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Spain	1.000000	0.03
Dexeus University Hospital, Spain	1.000000	0.03
Centro de Investigacións Mariñas (CIMA), Spain	0.666667	0.02
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain	0.666667	0.02
Cancer Research Center of Lyon (CRCL), France	0.500000	0.02
Lyon University Hospital (HCL), France	0.500000	0.02

Interested in Oncology and Carcinogenesis?